← Back to Screener
Trinity Biotech plc (TRIB)
Price$0.67
Value ScoreC
Growth ScoreD
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-44.35%
Price vs S&P 500 (4W)9.99%
VGM Score41.16
Market Capitalization$13.23M
All Metrics
Book Value / Share (Quarterly)$0.20
P/TBV (Annual)281.74x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-8.80%
Cash Flow / Share (Quarterly)$-0.02
Price vs S&P 500 (YTD)-23.66%
Gross Margin (TTM)31.82%
Net Profit Margin (TTM)-65.65%
EPS (TTM)$-0.10
10-Day Avg Trading Volume0.16M
EPS Excl Extra (TTM)$-0.10
Revenue Growth (5Y)-7.41%
EPS (Annual)$-0.09
ROI (Annual)-27.05%
Gross Margin (Annual)34.83%
Net Profit Margin (5Y Avg)-32.93%
Cash / Share (Quarterly)$0.00
Revenue Growth QoQ (YoY)-5.54%
ROA (Last FY)-30.78%
Revenue Growth TTM (YoY)-5.05%
EBITD / Share (TTM)$-0.06
ROE (5Y Avg)-161.55%
Operating Margin (TTM)-39.76%
Cash Flow / Share (Annual)$-0.47
P/B Ratio1.99x
P/B Ratio (Quarterly)3.37x
Net Income / Employee (Annual)$-79,300
EV / Revenue (TTM)2.30x
Net Interest Coverage (TTM)-2.21x
ROA (TTM)-36.27%
EV / EBITDA (TTM)1698.57x
EPS Incl Extra (Annual)$-0.09
Current Ratio (Annual)1.28x
Quick Ratio (Quarterly)0.47x
3-Month Avg Trading Volume0.16M
52-Week Price Return4.30%
Revenue / Employee (TTM)$140,000
Tangible BV / Share (Quarterly)$0.02
P/S Ratio (Annual)0.21x
Asset Turnover (Annual)0.60x
52-Week High$3.44
Operating Margin (5Y Avg)-21.60%
EPS Excl Extra (Annual)$-0.09
CapEx CAGR (5Y)-3.22%
Tangible BV CAGR (5Y)-67.56%
26-Week Price Return-36.43%
Quick Ratio (Annual)0.62x
13-Week Price Return-8.56%
Total Debt / Equity (Annual)21.68x
Current Ratio (Quarterly)1.03x
Enterprise Value$129.09M
Revenue / Share Growth (5Y)-30.59%
Asset Turnover (TTM)0.55x
Book Value / Share Growth (5Y)-52.97%
Revenue / Employee (Annual)$153,500
Inventory Turnover (Annual)2.04x
Pretax Margin (Annual)-49.92%
Cash / Share (Annual)$0.17
3-Month Return Std Dev74.90%
Gross Margin (5Y Avg)37.11%
Net Income / Employee (TTM)$-91,900
ROE (Last FY)-613.49%
Net Interest Coverage (Annual)-1.72x
EPS Basic Excl Extra (Annual)$-0.09
P/FCF (TTM)21.51x
Receivables Turnover (TTM)3.15x
Total Debt / Equity (Quarterly)8.73x
EPS Incl Extra (TTM)$-0.10
Receivables Turnover (Annual)4.91x
ROI (TTM)-24.46%
P/S Ratio (TTM)0.24x
Pretax Margin (5Y Avg)-38.76%
Revenue / Share (Annual)$0.17
Tangible BV / Share (Annual)$0.02
Price vs S&P 500 (52W)-20.07%
Year-to-Date Return-15.51%
5-Day Price Return-7.16%
EPS Normalized (Annual)$-0.09
ROA (5Y Avg)-23.97%
Net Profit Margin (Annual)-51.64%
Month-to-Date Return-5.02%
Cash Flow / Share (TTM)$-1.26
EBITD / Share (Annual)$-0.06
Operating Margin (Annual)-34.38%
LT Debt / Equity (Annual)17.40x
ROI (5Y Avg)-22.34%
LT Debt / Equity (Quarterly)8.70x
EPS Basic Excl Extra (TTM)$-0.10
P/TBV (Quarterly)281.74x
P/B Ratio (Annual)5.27x
Inventory Turnover (TTM)1.50x
Pretax Margin (TTM)-62.92%
Book Value / Share (Annual)$0.25
Price vs S&P 500 (13W)-16.82%
Beta1.00x
P/FCF (Annual)2.91x
Revenue / Share (TTM)$0.15
ROE (TTM)-166.14%
52-Week Low$0.50
vGradeC
gGradeD
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Oct 2022
Nov 2022
Dec 2022
Jan 2023
4.29
4.29
4.29
4.29
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TRIBTrinity Biotech plc | C | D | C | $0.67 |
| IDXXIdexx Laboratories Inc | D | B | C | $562.16 |
| LNTHLantheus Holdings, Inc | C | B | B | $100.98 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | B | $22.99 |
| CLDXCelldex Therapeutics, Inc | F | F | C | $28.62 |
| NEOGNeogen Corp | C | C | B | $8.90 |
| NTLAIntellia Therapeutics, Inc | D | C | B | $13.54 |
| QDELQuidelOrtho Corporation Common Stock | C | C | D | $14.33 |
| ACHVAchieve Life Sciences, Inc. | F | F | B | $5.13 |
| MYGNMyriad Genetics Inc | C | C | C | $4.57 |
| TKNOAlpha Teknova, Inc. Common Stock | C | C | B | $4.56 |
About
Trinity Biotech develops and manufactures clinical diagnostic products for laboratory and point-of-care testing, focusing on detection of autoimmune, infectious, and sexually transmitted diseases, as well as diabetes and organ-specific disorders. The company also supplies raw materials to the global life sciences and research industries. The Americas segment accounts for the majority of revenue.